High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer

The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer

(2016) M. Lennartz et al.   CLINICAL CANCER RESEARCH

Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens

(2016) Guido Sauter et al.   EUROPEAN UROLOGY

The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion

(2015) Christoph Burdelski et al.   BMC CANCER

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers

(2015) Christoph Burdelski et al.   PLoS One

γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation and gene expression in human colon and breast cancer cells

(2014) Sung-Eun Kim et al.   Genes and Nutrition

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression

(2014) Katharina Grupp et al.   INTERNATIONAL JOURNAL OF CANCER

NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer

(2014) Katharina Grupp et al.   PROSTATE

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer

(2013) Emman Shubbar et al.   BMC CANCER

Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies

(2013) Dejan Knezevic et al.   BMC GENOMICS

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate

(2013) S-E Kim et al.   BRITISH JOURNAL OF CANCER

Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

(2013) Joachim Weischenfeldt et al.   CANCER CELL

CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer

(2013) L. Burkhardt et al.   CANCER RESEARCH

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers

(2013) Laura Stumm et al.   JOURNAL OF CLINICAL PATHOLOGY

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressiveERGfusion-positive prostate cancers

(2013) Antje Krohn et al.   JOURNAL OF PATHOLOGY

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

(2013) Martina Kluth et al.   MODERN PATHOLOGY

High mitochondria content is associated with prostate cancer disease progression

(2013) Katharina Grupp et al.   Molecular Cancer

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades

(2012) Jonathan I. Epstein et al.   EUROPEAN UROLOGY

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling

(2011) Jan C Brase et al.   BMC CANCER

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

Epigenetics in Prostate Cancer: Biologic and Clinical Relevance

(2011) Carmen Jerónimo et al.   EUROPEAN UROLOGY

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study

(2011) Jack Cuzick et al.   LANCET ONCOLOGY

Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity

(2011) Michael Fenech   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Systems pharmacology assessment of the 5-fluorouracil pathway

(2011) Filipe A Muhale et al.   PHARMACOGENOMICS

FZD4 as a Mediator of ERG Oncogene-Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells

(2010) S. Gupta et al.   CANCER RESEARCH

Prevention by l-carnitine of DNA damage induced by propionic and l-methylmalonic acids in human peripheral leukocytes in vitro

(2010) Graziela S. Ribas et al.   MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS

Genoproteomic Mining of Urothelial Cancer Suggests γ-Glutamyl Hydrolase and Diazepam-Binding Inhibitor as Putative Urinary Markers of Outcome after Chemotherapy

(2009) Courtney Pollard et al.   AMERICAN JOURNAL OF PATHOLOGY

Integration ofERGgene mapping and gene-expression profiling identifies distinct categories of human prostate cancer

(2008) Sameer Jhavar et al.   BJU INTERNATIONAL

Low expression of γ-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype

(2008) K Kawakami et al.   BRITISH JOURNAL OF CANCER

Causes of and diagnostic approach to methylmalonic acidurias

(2008) B. Fowler et al.   JOURNAL OF INHERITED METABOLIC DISEASE